

BD solutions for enabling delivery of complex biologics

BD Evolve™ On-body Injector*



Experience

- Easy to use: activate, fill & apply⁶
- Ready for clinical trial testing in 2021
- **9 pre-clinical studies** conducted to evaluate injection performance and to inform device design⁵
- **5 human factor studies** conducted to inform device design⁶
- Automated manufacturing line has been established* to address the needs of an integrated medical device

Availability

- Available to support pharma clinical development
- Samples available upon request
- Data available to support combination product development

Key benefits

With this system BD strives to address 4 primary issues for pharma or healthcare systems:

- **Complexity and variability** in treatment regimens that may create hurdles to patient acceptance²
- Reduction of **healthcare costs** while improving outcomes and patient experience^{2,3}
- Need to **differentiate** drug therapies in an increasingly competitive market
- Desire for improved **data** about patient compliance⁴

With BD Evolve™ on-body injector, BD offers **flexibility** to serve design space requirements for **continuous, episodic, or delayed subcutaneous** delivery¹ of volumes up to **3 mL** for up to **3-day** wear.

The system is designed to be **programmable**, with **connected capabilities**,⁵ allowing for **convenient medication delivery** outside of acute care settings.

BD Evolve™ is a product in development; some statements made are forward-looking that are subject to regulatory approvals and a variety of risks and uncertainties.

BD Evolve™ On-body Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance.

* Process development to complete in 2021



References

1. BD REF-15917 BD Evolve™ Capabilities ver1.1
2. Hong Wen, Huijeong Jung, Xuhong Li. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. AAPS Journal, Vol 17, No 6, Nov. 2015. DOI: 10.11208/s12248-051-9814-9
3. Delgado Sanchez O. Comparative Cost Analysis of Intravenous and Subcutaneous Administration of Rituximab in Lymphoma Patients. Clinical Econ Outcomes Res 2019 Nov 18; 11:695-701
4. Bart J.F. van den Bemt, Lynda Gettings, Barbara Domanska, Richard Burggraber, Irina Mountian and Lars E. Kristensen
A portfolio of biologic self-injection devices in rheumatology; how patientinvolvement in device design can improve treatment experience
Drug Delivery 2019;26(1):384-392
5. Internal Data. BD REF-20428 BD Evolve™ Preclinical Studies 20201118 BDTI
6. BD-20969, BD Evolve™ List of Studies v1.0

BD Medical

Pharmaceutical Systems

United States

1 Becton Drive

Franklin Lakes, NJ 07417

+1 800 225 3310

Europe

11 rue Aristide-Bergès

38800 Le Pont-de-Claix

France

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05

Becton Dickinson France S.A.S - Share capital: 64 719 915 €

RCS Grenoble B 056 501 711

bd.com

